<DOC>
	<DOC>NCT00207025</DOC>
	<brief_summary>The purpose of this clinical research study is to learn about the safety and tolerability of daily BMS-275183 in patients with advanced cancer.</brief_summary>
	<brief_title>A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<criteria>Nonhematologic malignancy that has progressed or no standard therapy is known Four weeks from last chemotherapy or two weeks from last noncytotoxic therapy Eastern Cooperative Oncology Group (ECOG) Performance Status 01 No more than 3 prior chemotherapy regimens in advanced/metastatic setting Absolute neutrophil count &gt;=1,500/mm3 and platelets &gt;=100,000/mm3 Bilirubin &lt;=1.5 x Upper Limit of Normal (ULN), Aspartate aminotransferase &lt;=2.5 x ULN Serum creatinine &lt;=1.5 x ULN Men and women &gt;=18 years Women of Child Bearing Potential (WOCBP) must use adequate method of contraception throughout and up to 4 weeks after the study WOCBP and men not using adequate method of birth control WOCBP who are pregnant or breastfeeding Prior radiation &gt;=25% of bone marrow containing skeleton Uncontrolled, significant, or active cardiovascular or pulmonary disease or infection or psychiatric disorder Neuropathy Active brain metastases Inability to swallow capsules History of gastrointestinal disease, surgery or malabsorption, or requiring use of a feeding tube Concurrent chemotherapy, hormonal therapy, immunotherapy, or radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Patients with advanced solid tumors</keyword>
</DOC>